Status:
COMPLETED
Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis
Lead Sponsor:
Xinqiao Hospital of Chongqing
Conditions:
Radiation Pneumonitis
Endostatin
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To verify the efficacy and safety of endostatin in the treatment of SRILI（symptomatic radiation-induced lung injury） and fibrosis. The results of this study are expected to be a new clinical strategy ...
Detailed Description
Radiotherapy is an important treatment of lung cancer, symptomatic radiation-induced lung injury (SRILR) is the most common complications. In view of the important role of endostatin in inhibiting ang...
Eligibility Criteria
Inclusion
- Patients defined as NSCLC who could not be operated on, phase III-IV;
- EOCG PS: 0-3;
- The clinical diagnosis is RILI, with grade 2-3;
- No major organ dysfunction, such as heart failure and chronic obstructive pneumonia;
- No Endostar use contraindication;
- Volunteer to participate, good compliance, can cooperate with the test observation, and sign a written informed consent.
Exclusion
- Patient compliance is poor and violates the test regulations;
- Major organ dysfunction like liver and kidney occurs, such as myocardial infarction, angina pectoris, liver transaminase increased significantly;
- Hemorrhage or thrombus occurs, anticoagulant medication is required;
- Serious adverse drug reactions occur during treatment;
- The patient asked to be withdrawn from the trial;
- Other antiangiogenic drugs were used.
Key Trial Info
Start Date :
September 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2020
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT03796364
Start Date
September 1 2018
End Date
July 31 2020
Last Update
February 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xinqiao Hospital of Chongqing
Chongqing, China, 400000